Next Article in Journal
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Previous Article in Journal
Mass Spectrometric Characterization of Narcolepsy-Associated Pandemic 2009 Influenza Vaccines
Previous Article in Special Issue
Electroporation as the Immunotherapy Strategy for Cancer in Veterinary Medicine: State of the Art in Latin America
Open AccessArticle

A Novel Approach for the Treatment of T Cell Malignancies: Targeting T Cell Receptor Vβ Families

1
Division of Hematologic Malignancies and Cellular Therapies, Duke Cancer Institute, Durham, NC 27710, USA
2
Bristol-Meyers Squibb, 345 Park Ave, New York, NY 10154, USA
3
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
4
Department of Pathology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
5
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 631; https://doi.org/10.3390/vaccines8040631
Received: 24 August 2020 / Revised: 12 October 2020 / Accepted: 26 October 2020 / Published: 31 October 2020
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment)
Peripheral T cell lymphomas (PTCLs) are generally chemotherapy resistant and have a poor prognosis. The lack of targeted immunotherapeutic approaches for T cell malignancies results in part from potential risks associated with targeting broadly expressed T cell markers, namely T cell depletion and clinically significant immune compromise. The knowledge that the T cell receptor (TCR) β chain in human α/β TCRs are grouped into Vβ families that can each be targeted by a monoclonal antibody can therefore be exploited for therapeutic purposes. Here, we develop a flexible approach for targeting TCR Vβ families by engineering T cells to express a chimeric CD64 protein that acts as a high affinity immune receptor (IR). We found that CD64 IR-modified T cells can be redirected with precision to T cell targets expressing selected Vβ families by combining CD64 IR-modified T cells with a monoclonal antibody directed toward a specific TCR Vβ family in vitro and in vivo. These findings provide proof of concept that TCR Vβ-family-specific T cell lysis can be achieved using this novel combination cell–antibody platform and illuminates a path toward high precision targeting of T cell malignancies without substantial immune compromise. View Full-Text
Keywords: T cell lymphoma; T cell receptor; antibodies; immunotherapy; CD64; immune receptor T cell lymphoma; T cell receptor; antibodies; immunotherapy; CD64; immune receptor
Show Figures

Figure 1

MDPI and ACS Style

Wang, J.; Urbanska, K.; Sharma, P.; Nejati, R.; Shaw, L.; Lim, M.S.; Schuster, S.J.; Jr., D.J.P. A Novel Approach for the Treatment of T Cell Malignancies: Targeting T Cell Receptor Vβ Families. Vaccines 2020, 8, 631. https://doi.org/10.3390/vaccines8040631

AMA Style

Wang J, Urbanska K, Sharma P, Nejati R, Shaw L, Lim MS, Schuster SJ, Jr. DJP. A Novel Approach for the Treatment of T Cell Malignancies: Targeting T Cell Receptor Vβ Families. Vaccines. 2020; 8(4):631. https://doi.org/10.3390/vaccines8040631

Chicago/Turabian Style

Wang, Jie; Urbanska, Katarzyna; Sharma, Prannda; Nejati, Reza; Shaw, Lauren; Lim, Megan S.; Schuster, Stephen J.; Jr., Daniel J.P. 2020. "A Novel Approach for the Treatment of T Cell Malignancies: Targeting T Cell Receptor Vβ Families" Vaccines 8, no. 4: 631. https://doi.org/10.3390/vaccines8040631

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop